Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04937751

Markers of Infection and Resistance in Invasive Fusariosis

Multicenter Study on Invasive Fusariosis : Looking for Markers of Infection and Resistance

Status
Recruiting
Phase
Study type
Observational
Enrollment
150 (estimated)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

In recent decades, invasive fusarioses have been emerging fungal pathologies with high mortality. The prognosis depends on the speed of the diagnosis, but currently biological diagnosis is mainly based on fungal culture, no specific biomarker for this microorganism is available in current clinical practice. The genus Fusarium also shows reduced sensitivity to antifungals commonly used and recommended in clinical practice, such as voriconazole or amphotericin B. The main objective of this study is to describe the proportions of different fungal species in positive fungal cultures in patients with invasive fungal infection (IFI) or fungal keratitis. The secondary objectives are the description of the dosage of galactomannans, beta (1,3) -D-glucans and the rate of detection of DNA circulating in case / control groups for the 2 clinical forms studied. In patients with evidence of Fusarium wilt, the study will describe the distribution of the different minimum inhibitory concentrations (MIC) depending on whether or not different antifungals are taken, the vital status at 3 months, and the response or not to treatment. Finally, the presence of genetic markers will be described according to the groups of MIC values.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTbiomarkersgalactomannan, betaDglucan, resistance markers

Timeline

Start date
2023-07-19
Primary completion
2028-07-01
Completion
2028-07-01
First posted
2021-06-24
Last updated
2024-02-23

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04937751. Inclusion in this directory is not an endorsement.